{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:12:10Z","timestamp":1787026330675,"version":"build-2736575974"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2020.00325","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T06:23:43Z","timestamp":1593498223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["HCV Replicon Systems: Workhorses of Drug Discovery and Resistance"],"prefix":"10.3389","volume":"10","author":[{"given":"Shaheen","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Suresh","family":"Veerapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e01932","DOI":"10.1128\/JVI.01932-17","article-title":"Novel synthesis and phenotypic analysis of mutant clouds for hepatitis E virus genotype 1","volume":"92","author":"Agarwal","year":"2018","journal-title":"J. Virol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.3390\/v7122968","article-title":"Mechanisms of hepatitis C viral resistance to direct acting antivirals","volume":"7","author":"Ahmed","year":"2015","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1155\/2013\/624986","article-title":"Epidemiology and treatment of hepatitis C genotypes 5 and 6","volume":"27","author":"Al Naamani","year":"2013","journal-title":"Can. J. Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/v11010030","article-title":"Overview of HCV life cycle with a special focus on current and possible future antiviral targets","volume":"11","author":"Alazard-Dany","year":"2019","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1128\/JVI.79.5.3187-3194.2005","article-title":"Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain","volume":"79","author":"Appel","year":"2005","journal-title":"J. Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01280-18","article-title":"In vitro antiviral profile of ruzasvir, a potent and pangenotype inhibitor of hepatitis C virus NS5a","volume":"62","author":"Asante-Appiah","year":"2018","journal-title":"Antimicrob. Agents Chemother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/v11020148","article-title":"Geographic distribution of HCV-GT3 subtypes and naturally occurring resistance associated substitutions","volume":"11","author":"Bagaglio","year":"2019","journal-title":"Viruses"},{"key":"B9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/nrd942","article-title":"Hepatitis C virus replicons: potential role for drug development","volume":"1","author":"Bartenschlager","year":"2002","journal-title":"Nat. Rev. Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.mib.2006.06.012","article-title":"Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture","volume":"9","author":"Bartenschlager","year":"2006","journal-title":"Curr. Opin. Microbiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat. Rev. Microbiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J. Exp. Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/j.1460-2075.1996.tb00329.x","article-title":"Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus","volume":"15","author":"Behrens","year":"1996","journal-title":"EMBO J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1128\/jvi.77.5.3181-3190.2003","article-title":"Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture","volume":"77","author":"Blight","year":"2003","journal-title":"J. Virol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1086\/651579","article-title":"Challenge pools of hepatitis C virus genotypes 1\u20136 prototype strains: Replication fitness and pathogenicity in chimpanzees and human liver\u2013chimeric mouse models","volume":"201","author":"Bukh","year":"2010","journal-title":"J. Infect. Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.virol.2017.11.003","article-title":"Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems","volume":"514","author":"Camus","year":"2018","journal-title":"Virology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cld.2015.06.002","article-title":"Meet the classes of directly acting antiviral agents","volume":"19","author":"Chacko","year":"2015","journal-title":"Clin. Liver Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40265-016-0685-x","article-title":"Genotype 3 Infection: The last stand of hepatitis C Virus","volume":"77","author":"Chan","year":"2017","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S484","DOI":"10.1016\/S0168-8278(13)61192-7","article-title":"1191 GS-5816, A second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier","volume":"58","author":"Cheng","year":"2013","journal-title":"J. Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/cmdc.201300343","article-title":"Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity","volume":"8","author":"Coburn","year":"2013","journal-title":"ChemMedChem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/rmv.1895","article-title":"Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time","volume":"26","author":"Cuypers","year":"2016","journal-title":"Rev. Med. Virol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1872-034X.2007.00056.x","article-title":"An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain","volume":"37","author":"Date","year":"2007","journal-title":"Hepatol. Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DeGoey","year":"2014","journal-title":"J. Med. Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex","volume":"76","author":"Egger","year":"2002","journal-title":"J. Virol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13038","DOI":"10.1073\/pnas.0405152101","article-title":"Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication","volume":"101","author":"Evans","year":"2004","journal-title":"Proc. Natl. Acad. Sci U.S.A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cld.631","article-title":"Resistance testing: Interpretation and incorporation into HCV treatment algorithms","volume":"9","author":"Feld","year":"2017","journal-title":"Clin. Liver Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent","volume":"63","author":"Forns","year":"2015","journal-title":"J. Hepatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e25058","DOI":"10.1002\/jia2.25058","article-title":"Approaches for simplified HCV diagnostic algorithms","volume":"21","author":"Fourati","year":"2018","journal-title":"J. Int. AIDS Soc"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.3390\/v7122941","article-title":"Virologic tools for HCV drug resistance testing","volume":"7","author":"Fourati","year":"2015","journal-title":"Viruses"},{"key":"B37","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1053\/jhep.2002.31770","article-title":"Interferon-\u03b3 inhibits replication of subgenomic and genomic hepatitis C virus RNAs","volume":"35","author":"Frese","year":"2002","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1038\/nmicrobiol.2016.45","article-title":"Highly heterogeneous mutation rates in the hepatitis C virus genome","volume":"1","author":"Geller","year":"2016","journal-title":"Nat. Microbiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.coviro.2012.08.004","article-title":"The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance","volume":"2","author":"G\u00f6tte","year":"2012","journal-title":"Curr. Opin. Virol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrgastro.2016.60","article-title":"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights","volume":"13","author":"G\u00f6tte","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (Strain S52) and 4a (Strain ED43): genetic analyses and in vivo pathogenesis studies","volume":"84","author":"Gottwein","year":"2010","journal-title":"J. Virol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10583","DOI":"10.1073\/pnas.90.22.10583","article-title":"A second hepatitis C virus-encoded proteinase","volume":"90","author":"Grakoui","year":"1993","journal-title":"Proc. Natl. Acad. Sci U.S.A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"16741","DOI":"10.1074\/jbc.M212602200","article-title":"Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase","volume":"278","author":"Grobler","year":"2003","journal-title":"J. Biol. Chem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"104612","DOI":"10.1016\/j.antiviral.2019.104612","article-title":"Construction and characterization of genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness","volume":"171","author":"Guo","year":"2019","journal-title":"Antiviral. Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"104574","DOI":"10.1016\/j.antiviral.2019.104574","article-title":"Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-na\u00efve subjects","volume":"170","author":"Han","year":"2019","journal-title":"Antiviral Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"16247","DOI":"10.1038\/nmicrobiol.2016.247","article-title":"Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture","volume":"2","author":"Harak","year":"2017","journal-title":"Nat. Microbiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/jvh.12405","article-title":"Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy","volume":"22","author":"Hedskog","year":"2015","journal-title":"J. Viral Hepat"},{"key":"B50","doi-asserted-by":"publisher","first-page":"ofz076","DOI":"10.1093\/ofid\/ofz076","article-title":"Identification of 19 Novel hepatitis C virus subtypes\u2014further expanding HCV classification","volume":"6","author":"Hedskog","year":"2019","journal-title":"Open Forum Infect. Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1128\/AAC.00533-08","article-title":"Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors","volume":"52","author":"Herlihy","year":"2008","journal-title":"Antimicrob. Agents Chemother"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/S0140-6736(18)32326-2","article-title":"Direct-acting antiviral treatment for hepatitis C","volume":"393","author":"Holmes","year":"2019","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N. Engl. J. Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1128\/JVI.76.6.2997-3006.2002","article-title":"Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells","volume":"76","author":"Ikeda","year":"2002","journal-title":"J. Virol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/hep.30647","article-title":"Evolutionary pathways to persistence of highly fit and resistant hepatitis C virus protease inhibitor escape variants","volume":"70","author":"Jensen","year":"2019","journal-title":"Hepatology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1478-3231.2010.02385.x","article-title":"Hepatitis C virus genotype 4 therapy: progress and challenges","volume":"31","author":"Kamal","year":"2011","journal-title":"Liver Int"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1053\/j.gastro.2003.09.023","article-title":"Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon","volume":"125","author":"Kato","year":"2003","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/jmv.1055","article-title":"Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient","volume":"64","author":"Kato","year":"2001","journal-title":"J. Med. Virol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1128\/jvi.75.10.4614-4624.2001","article-title":"Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations","volume":"75","author":"Krieger","year":"2001","journal-title":"J. Virol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"","journal-title":"Antimicrob. Agents Chemother"},{"key":"B63","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"","journal-title":"Antimicrob. Agents Chemother"},{"key":"B64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J. Hepatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother"},{"key":"B66","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-8976-8_1","article-title":"Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus","volume":"1911","author":"Li","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.virol.2004.12.031","article-title":"Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells","volume":"333","author":"Liang","year":"2005","journal-title":"Virology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"8147","DOI":"10.1128\/JVI.68.12.8147-8157.1994","article-title":"Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics","volume":"68","author":"Lin","year":"1994","journal-title":"J. Virol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nature04077","article-title":"Unravelling hepatitis C virus replication from genome to function","volume":"436","author":"Lindenbach","year":"2005","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob. Agents Chemother"},{"key":"B73","first-page":"145","article-title":"HCV Replicons: Overview and basic protocols","volume-title":"Methods in Molecular Biology","author":"Lohmann","year":"2009"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1128\/JVI.77.5.3007-3019.2003","article-title":"Viral and cellular determinants of hepatitis C virus RNA replication in cell culture","volume":"77","author":"Lohmann","year":"2003","journal-title":"J. Virol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1128\/JVI.75.3.1437-1449.2001","article-title":"Mutations in hepatitis C virus RNAs conferring cell culture adaptation","volume":"75","author":"Lohmann","year":"2001","journal-title":"J. Virol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.1128\/JVI.71.11.8416-8428.1997","article-title":"Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity","volume":"71","author":"Lohmann","year":"1997","journal-title":"J. Virol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e15626","DOI":"10.1097\/MD.0000000000015626","article-title":"Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6","volume":"98","author":"Luo","year":"2019","journal-title":"Medicine"},{"key":"B80","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1478-3231.2011.02710.x","article-title":"What's new in HCV genotype 2 treatment?","volume":"32","author":"Mangia","year":"2012","journal-title":"Liver Int"},{"key":"B81","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1016\/S0168-8278(09)60957-0","article-title":"955 Preclinical potency, pharmacokinetic and ADME characterization of ABT-333, a novel non-nucleoside HCV polymerase inhibitor","volume":"50","author":"Maring","year":"2009","journal-title":"J. Hepatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1128\/AAC.01317-07","article-title":"The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors","volume":"52","author":"McCown","year":"2008","journal-title":"Antimicrob. Agents Chemother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.1128\/JVI.78.14.7400-7409.2004","article-title":"Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes","volume":"78","author":"Moradpour","year":"2004","journal-title":"J. Virol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat. Rev. Microbiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1128\/JVI.77.5.2928-2935.2003","article-title":"Persistent replication of hepatitis C virus replicons expressing the \u03b2-Lactamase reporter in subpopulations of highly permissive Huh7 Cells","volume":"77","author":"Murray","year":"2003","journal-title":"J. Virol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"B88","first-page":"7","article-title":"A next generation HCV DAA combination: potent, pangenotypic inhibitors ABT-493 and ABT-530 with high barriers to resistance. [abstract]","volume-title":"65th Annual Meeting of the American Association for the Study of Liver Diseases 2014","author":"Ng","year":"2014"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02558-16","article-title":"In Vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"","journal-title":"Antimicrob. Agents Chemother"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01620-17","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C Virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"","journal-title":"Antimicrob. Agents Chemother"},{"key":"B91","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/apt.15043","article-title":"Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir","volume":"49","author":"Nguyen","year":"2019","journal-title":"Aliment. Pharmacol. Ther"},{"key":"B92","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1542-3565(05)00711-1","article-title":"Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6","volume":"3","author":"Nguyen","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus","volume":"88","author":"Ogata","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1128\/AAC.02776-15","article-title":"Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6","volume":"60","author":"Pati\u00f1o-Galindo","year":"2016","journal-title":"Antimicrob. Agents Chemother"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1473-3099(12)70060-9","article-title":"Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care","volume":"12","author":"Pearlman","year":"2012","journal-title":"Lancet Infect. Dis"},{"key":"B98","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2012.09.033","article-title":"Development of robust hepatitis C virus genotype 4 subgenomic replicons","volume":"144","author":"Peng","year":"2013","journal-title":"Gastroenterology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3390\/v7112902","article-title":"Resistance of hepatitis C virus to inhibitors: complexity and clinical implications","volume":"7","author":"Perales","year":"2015","journal-title":"Viruses"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1053\/j.gastro.2018.02.017","article-title":"HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models","volume":"154","author":"Pham","year":"2018","journal-title":"Gastroenterology"},{"key":"B101","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1128\/JVI.76.8.4008-4021.2002","article-title":"Persistent and transient replication of full-length hepatitis C virus genomes in cell culture","volume":"76","author":"Pietschmann","year":"2002","journal-title":"J. Virol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e1000475","DOI":"10.1371\/journal.ppat.1000475","article-title":"Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations","volume":"5","author":"Pietschmann","year":"2009","journal-title":"PLoS Pathog"},{"key":"B103","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob. Agents Chemother"},{"key":"B104","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2055-6640(20)30264-8","article-title":"Report from the international viral hepatitis elimination meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework","volume":"4","author":"Popping","year":"2018","journal-title":"J. Virus Erad"},{"key":"B105","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.antiviral.2018.07.014","article-title":"Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: essential tools in testing of antivirals and emerging vaccine strategies","volume":"158","author":"Ramirez","year":"2018","journal-title":"Antiviral Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/hep.26660","article-title":"Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors","volume":"59","author":"Ramirez","year":"2014","journal-title":"Hepatology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e1003359","DOI":"10.1371\/journal.ppat.1003359","article-title":"The lipid kinase phosphatidylinositol-4 kinase iii alpha regulates the phosphorylation status of hepatitis C virus NS5A","volume":"9","author":"Reiss","year":"2013","journal-title":"PLoS Pathog"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/hep.31182","article-title":"Hepatitis C vaccine: 10 good reasons for continuing","volume":"71","author":"Roingeard","year":"2020","journal-title":"Hepatology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e1003056","DOI":"10.1371\/journal.ppat.1003056","article-title":"Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication","volume":"8","author":"Romero-Brey","year":"2012","journal-title":"PLoS Pathog"},{"key":"B111","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature14899","article-title":"SEC14L2 enables pan-genotype HCV replication in cell culture","volume":"524","author":"Saeed","year":"2015","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.gastro.2012.09.017","article-title":"Replication of hepatitis C virus genotype 3a in cultured cells","volume":"144","author":"Saeed","year":"2013","journal-title":"Gastroenterology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1128\/AAC.01256-12","article-title":"Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells","volume":"56","author":"Saeed","year":"2012","journal-title":"Antimicrob. Agents Chemother"},{"key":"B114","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat. Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.02929-15","article-title":"Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants: In vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle","volume":"60","author":"Serre","year":"2016","journal-title":"Antimicrob. Agents Chemother"},{"key":"B116","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3851\/IMP1825","article-title":"Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates","volume":"16","author":"Sheaffer","year":"2011","journal-title":"Antivir. Ther"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01327-19","article-title":"Genome-wide mutagenesis of hepatitis C virus reveals ability of genome to overcome detrimental mutations","volume":"94","author":"Singh","year":"2020","journal-title":"J. Virol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"18036","DOI":"10.1074\/jbc.M111.320085","article-title":"Replication of hepatitis C virus RNA on autophagosomal membranes","volume":"287","author":"Sir","year":"2012","journal-title":"J. Biol. Chem"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/hep.29837","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","volume":"69","author":"Smith","year":"2019","journal-title":"Hepatology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"B121","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4A protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob. Agents Chemother"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1128\/jvi.69.7.3980-3986.1995","article-title":"Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A","volume":"69","author":"Tanji","year":"1995","journal-title":"J. Virol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/j.bmcl.2019.03.037","article-title":"Discovery of the pan-genotypic hepatitis C virus NS3\/4A protease inhibitor voxilaprevir (GS-9857): a component of Vosevi\u00ae","volume":"29","author":"Taylor","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B124","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1128\/JVI.67.7.4017-4026.1993","article-title":"NS3 is a serine protease required for processing of hepatitis C virus polyprotein","volume":"67","author":"Tomei","year":"1993","journal-title":"J. Virol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1021\/acs.jmedchem.6b01310","article-title":"Discovery of ruzasvir (MK-8408): A potent, pan-genotype HCV NS5A inhibitor with optimized activity against common resistance-associated polymorphisms","volume":"60","author":"Tong","year":"2017","journal-title":"J. Med. Chem"},{"key":"B126","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0166-0934(03)00134-4","article-title":"A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C","volume":"110","author":"Vrolijk","year":"2003","journal-title":"J. Virol. Methods"},{"key":"B127","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/2049936113502647","article-title":"An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials","volume":"1","author":"Wendt","year":"2013","journal-title":"Ther. Adv. Infect. Dis"},{"key":"B129","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.gastro.2019.05.007","article-title":"Amino acid substitutions in genotype 3a hepatitis c virus polymerase protein affect responses to sofosbuvir","volume":"157","author":"Wing","year":"2019","journal-title":"Gastroenterology"},{"key":"B130","volume-title":"Global Hepatitis Report 2017","year":"2017"},{"key":"B131","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.1128\/AAC.03534-14","article-title":"Hepatitis C Virus Genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents","volume":"58","author":"Wose Kinge","year":"2014","journal-title":"Antimicrob. Agents Chemother"},{"key":"B132","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","article-title":"Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir","volume":"66","author":"Wyles","year":"2017","journal-title":"J. Hepatol"},{"key":"B133","first-page":"103","article-title":"Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens","volume":"25","author":"Wyles","year":"2017","journal-title":"Top. Antivir. Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1128\/AAC.00487-13","article-title":"Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451","volume":"58","author":"Yang","year":"2014","journal-title":"Antimicrob. Agents Chemother"},{"key":"B135","doi-asserted-by":"publisher","first-page":"7904","DOI":"10.1128\/JVI.78.15.7904-7915.2004","article-title":"Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal huh7 cells","volume":"78","author":"Yi","year":"2004","journal-title":"J. Virol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1073\/pnas.0510727103","article-title":"Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells","volume":"103","author":"Yi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B137","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1128\/AAC.01780-13","article-title":"Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture","volume":"58","author":"Yu","year":"2014","journal-title":"Antimicrob. Agents Chemother"},{"key":"B138","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T07:16:33Z","timestamp":1616397393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":139,"alternative-id":["10.3389\/fcimb.2020.00325"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2020.00325","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"article-number":"325"}}